PolyPid director reports stock option holdings

PolyPid Ltd. director Robert Benjamin Stein reported his existing holdings of stock options to purchase Ordinary Shares.

Rhea-AI Filing Summary

PolyPid Ltd. director Robert Benjamin Stein reported his existing holdings of stock options to purchase Ordinary Shares. These options cover individual blocks such as 312 shares at an exercise price of 11.4000 per share expiring on 2033-05-05 and 6,500 shares at 4.2400 per share expiring on 2034-07-02. Another grant for 14,440 underlying shares has an exercise price of 2.6700 per share and expires on 2035-06-25, with vesting on a quarterly basis through 2029. Several earlier grants are already fully vested, reflecting established equity-based compensation rather than new market transactions.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Stein Robert Benjamin

Role Director

Type	Security	Shares	Price	Value
holding	Stock option (right to buy)	--	--	--
holding	Stock option (right to buy)	--	--	--
holding	Stock option (right to buy)	--	--	--
holding	Stock option (right to buy)	--	--	--
holding	Stock option (right to buy)	--	--	--
holding	Stock option (right to buy)	--	--	--

Holdings After Transaction: Stock option (right to buy) — 22,660 contracts (Direct)

Footnotes (6)

1. F1. The options were granted on May 5, 2023 and fully vested as of May 5, 2024.
2. F2. The options were granted on June 18, 2020 and fully vested as of June 4, 2023.
3. F3. The options were granted on April 13, 2021 and fully vested as of April 13, 2022.
4. F4. The options were granted on May 3, 2022 and fully vested as of May 3, 2023.
5. F5. The options were granted on July 2, 2024 and fully vested as of July 2, 2025.
6. F6. The options were granted on June 25, 2025 and vest on a quarterly basis beginning May 12, 2025 until May 12, 2029.

Key Figures

Option grant: 312 underlying shares at 11.4000 Option grant: 6,500 underlying shares at 4.2400 Option grant: 14,440 underlying shares at 2.6700

3 metrics

Option grant 312 underlying shares at 11.4000 Stock option expiring 2033-05-05, fully vested by 2024-05-05

Option grant 6,500 underlying shares at 4.2400 Stock option expiring 2034-07-02, fully vested by 2025-07-02

Option grant 14,440 underlying shares at 2.6700 Grant dated 2025-06-25, expires 2035-06-25, vests quarterly to 2029-05-12

Key Terms

Stock option (right to buy), Ordinary Shares, fully vested, vest on a quarterly basis

4 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

Ordinary Shares financial

"underlying_security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

fully vested financial

"The options were granted on May 5, 2023 and fully vested as of May 5, 2024."

vest on a quarterly basis financial

"The options were granted on June 25, 2025 and vest on a quarterly basis"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does PolyPid (PYPD) director Robert Benjamin Stein report in this Form 3?

Robert Benjamin Stein reports his existing holdings of stock options to purchase PolyPid Ordinary Shares. The filing lists multiple option grants with specific exercise prices, share amounts, vesting schedules, and expiration dates, showing his current equity-based compensation position rather than new trades.

How many PolyPid (PYPD) shares are covered by Stein’s largest stock option grant?

Stein’s largest listed stock option grant covers 14,440 underlying Ordinary Shares. This grant has an exercise price of 2.6700 per share, expires on 2035-06-25, and vests on a quarterly basis beginning May 12, 2025, continuing until May 12, 2029.

What are some key exercise prices on Robert Benjamin Stein’s PolyPid (PYPD) options?

Stein’s options include exercise prices of 11.4000, 23.0700, 4.2400 and 2.6700 per underlying Ordinary Share. Each exercise price is tied to a specific grant, share amount, and expiration date, illustrating a range of potential purchase costs over time.

When do Robert Benjamin Stein’s PolyPid (PYPD) stock options expire?

Stein’s reported option grants have expiration dates spanning from 2030-06-18 through 2035-06-25. For example, one 312-share grant expires on 2033-05-05, while the 14,440-share grant with a 2.6700 exercise price expires on 2035-06-25.

Are Robert Benjamin Stein’s PolyPid (PYPD) stock options already vested?

Several grants are fully vested, including options granted on May 5, 2023, June 18, 2020, April 13, 2021, May 3, 2022, and July 2, 2024. Another grant dated June 25, 2025 for 14,440 shares vests quarterly from May 12, 2025 until May 12, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/06/2026 - 08:01 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Stein Robert Benjamin

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET ISRAEL

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	08/05/2023	05/05/2033	Ordinary Shares	312(1)	$11.4	D
Stock option (right to buy)	06/04/2021	06/18/2030	Ordinary Shares	797(2)	$23.07	D
Stock option (right to buy)	07/13/2021	04/13/2031	Ordinary Shares	299(3)	$23.07	D
Stock option (right to buy)	08/03/2022	05/03/2032	Ordinary Shares	312(4)	$23.07	D
Stock option (right to buy)	10/02/2024	07/02/2034	Ordinary Shares	6,500(5)	$4.24	D
Stock option (right to buy)	08/12/2025	06/25/2035	Ordinary Shares	14,440(6)	$2.67	D

Explanation of Responses:

1. The options were granted on May 5, 2023 and fully vested as of May 5, 2024.

2. The options were granted on June 18, 2020 and fully vested as of June 4, 2023.

3. The options were granted on April 13, 2021 and fully vested as of April 13, 2022.

4. The options were granted on May 3, 2022 and fully vested as of May 3, 2023.

5. The options were granted on July 2, 2024 and fully vested as of July 2, 2025.

6. The options were granted on June 25, 2025 and vest on a quarterly basis beginning May 12, 2025 until May 12, 2029.

	/s/ Robert Benjamin Stein	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)